- Active not recruitingPHASE1
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
This study is looking at a new drug called CC-97540 for people with certain types of Multiple Sclerosis (MS) or a muscle weakness condition called Myasthenia Gravis (MG). We want to see if it's safe, how well people can handle it, and if it helps their condition.
For: Multiple Sclerosis · Myasthenia GravisUnited States · Belgium · France - Active not recruitingPHASE3
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
This study looks at new treatments for multiple myeloma, a type of blood cancer. It compares a standard treatment plus a new cell therapy called cilta-cel, against the standard treatment alone, for people newly diagnosed who aren't having a stem cell transplant initially.
For: Multiple MyelomaUnited States · Argentina · Australia - Active not recruitingPHASE3
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
This study looks at new ways to treat children with a type of blood cancer called Acute Myeloid Leukaemia (AML). It compares different chemotherapy drugs, including a drug called gemtuzumab ozogamicin, and different types of stem cell transplants to find the most effective and safest treatments for young patients.
For: Acute Myeloid LeukaemiaAustralia · France · Ireland - Not yet recruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
This study looks at a new treatment called BMS-986353 for severe Systemic Sclerosis. It compares this new treatment with standard care to see if it's more effective and safe for people with this condition.
For: Systemic SclerosisUnited States · Belgium · Canada - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
This study compares a new treatment called BMS-986393 with standard medicines for adults with multiple myeloma that has come back or not responded to previous treatment, including lenalidomide. We want to see if the new medicine works better and is safe.
For: Relapsed or Refractory Multiple Myeloma (RRMM)United States · Argentina · Australia - Active not recruitingPHASE3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
This study compares a new treatment called anitocabtagene autoleucel with standard care for people with multiple myeloma that has come back or not responded to previous treatments. It aims to see if the new treatment works better.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE1, PHASE2
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
This study is testing a new cell therapy called gavo-cel for advanced cancers like mesothelioma and ovarian cancer. It explores how well gavo-cel works, both alone and with other cancer drugs, in people whose tumours produce a specific protein called mesothelin.
For: Mesothelioma · Mesothelioma, Malignant · Mesothelioma; PleuraUnited States · Canada - RecruitingPHASE3
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
This study looks at a new drug called venetoclax for children, teenagers, and young adults with acute myeloid leukaemia (AML) that has come back. It aims to see if adding venetoclax to standard chemotherapy can help improve their chances of survival.
For: Acute Myeloid LeukemiaUnited States · Australia · Austria - Active not recruitingPHASE2
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
This study is testing a new combination of treatments for children and teenagers with a certain type of acute myeloid leukemia (FLT3-mutated AML). It combines a drug called midostaurin with standard chemotherapy to see if it's safe and effective for these patients.
For: FLT3-mutated Acute Myeloid LeukemiaCzechia · Germany · Italy - RecruitingPHASE1
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
This study is testing a new cell therapy called ZI-MA4-1 for certain advanced cancers like ovarian, lung, and head and neck cancer. It's the first time this treatment designed to fight cancer will be given to people, aiming to see if it's safe and how well it works.
For: Ovarian Cancer · Squamous Non-Small Cell Lung Cancer (NSCLC) · Synovial SarcomasUnited Kingdom - RecruitingPHASE3
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
This study is for people recently diagnosed with a type of blood cancer called multiple myeloma who can't have a stem cell transplant. It compares a new medicine called AZD0120 with current standard treatments to see if it works better at controlling the cancer and keeping people well for longer.
For: Newly Diagnosed Multiple MyelomaUnited States · Australia · Brazil - Active not recruitingPHASE3
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
This study compares two treatments for newly diagnosed multiple myeloma. One treatment uses a drug combination followed by a cell therapy (Cilta-cel). The other uses the same drug combination followed by a stem cell transplant. The aim is to see which works best.
For: Multiple MyelomaUnited States · Australia · Belgium - RecruitingPHASE2
Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT
This study compares two drug combinations (Clofarabine vs. Fludarabine) to improve survival in adults with a type of blood cancer called Acute Myeloid Leukemia (AML) who are having a stem cell transplant. It aims to see if one combination works better.
For: Acute Myeloid Leukemia in RemissionFrance - RecruitingPHASE2
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
This study is looking at a new type of treatment called liso-cel for adults with a brain lymphoma that can't have a stem cell transplant. It aims to see how safe and effective this new treatment is as the first treatment they receive.
For: LymphomaUnited States · France · Germany - Active not recruitingPHASE2
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
This study is looking at new ways to treat newly diagnosed multiple myeloma. It compares different combinations of new and existing medicines to see which ones work best to control the cancer and potentially lead to long-lasting remission.
For: Multiple MyelomaUnited States · Australia · Brazil - RecruitingPHASE1
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
This study is testing a new type of cell therapy called BMS-986515 for severe autoimmune diseases like lupus and arthritis. Doctors want to find out if it's safe, what dose works best, and if it can help people whose current treatments aren't effective.
For: Refractory Autoimmune DiseasesUnited States · Australia · Brazil - Active not recruitingPHASE2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
This study is testing a new cell therapy called CC-97540 for people with lupus and lupus kidney disease. It aims to see if it's safe and effective when other treatments haven't worked well enough.
For: Lupus Erythematosus, Systemic · Lupus NephritisUnited States · Argentina · Austria - Active not recruitingPHASE2
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
This study looks at a new cell therapy called Lete-Cel for certain advanced cancers like synovial sarcoma and myxoid/round cell liposarcoma. It aims to see how safe and effective this treatment is for people whose cancer hasn't responded to previous treatments.
For: NeoplasmsUnited States · Canada · France - Active not recruitingPHASE2
Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation
This study is for children under 13 with sickle cell disease who have a healthy sibling donor. It looks at a special type of bone marrow transplant to see if it's safe and effective, aiming to improve long-term health and quality of life for these children.
For: Sickle Cell DiseaseUnited States · Canada - Active not recruitingPHASE3
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
This study compares a new treatment, axicabtagene ciloleucel, with standard care for adults recently diagnosed with high-risk large B-cell lymphoma. It aims to see if the new treatment works better as a first treatment option.
For: High-risk Large B-cell Lymphoma (LBCL)United States · Australia · Austria - RecruitingPHASE1
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
This study in Canada tests a new treatment, GCAR1, for specific advanced cancers like certain breast, kidney, and bone cancers. Researchers want to find the safest dose and see if it helps slow down cancer by using the body's own immune cells.
For: Alveolar Soft Part Sarcoma · Renal Cell Carcinoma · Triple Negative Breast CancerCanada - RecruitingPHASE1, PHASE2
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
This study is testing a new treatment called AZD0120 for severe lupus (Systemic Lupus Erythematosus) that hasn't responded to other medicines. It aims to see if the treatment is safe, how well people tolerate it, and if it helps improve lupus symptoms in adults.
For: Lupus Erythematosus, SystemicUnited States · Australia · Canada - RecruitingPHASE1
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
This study is testing a new medicine called FT819 for serious autoimmune diseases like lupus and vasculitis. It's looking at how safe it is and how well it works to reduce disease activity, especially in those who haven't responded to other treatments.
For: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV) · Idiopathic Inflammatory Myositis (IIM) · Systemic Sclerosis (SSc)United States · France · Sweden - Active not recruitingPHASE2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
This study looks at a new treatment called lete-cel for certain advanced cancers like synovial sarcoma and myxoid/round cell liposarcoma. It uses specially modified immune cells to fight cancer, testing how safe and effective it is for people with specific cancer markers.
For: NeoplasmsUnited States · Canada · France - RecruitingPHASE2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This study helps doctors find the best treatments for people with certain blood cancers like leukaemia. It uses special tests on blood and bone marrow to match patients with personalised treatments or standard care, aiming to improve how cancer treatments are chosen.
For: Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic TherapyUnited States · Canada · Puerto Rico - RecruitingPHASE2, PHASE3
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
This study looks at a new way to treat children and teenagers with a type of blood cancer called Acute Lymphoblastic Leukaemia (ALL). It compares standard treatment with a new approach using chemotherapy instead of radiation, aiming to reduce long-term side effects.
For: Acute Lymphoblastic LeukaemiaArgentina · Australia · Austria - RecruitingPHASE2
DALY II USA/ MB-CART2019.1 for DLBCL
This study is testing a new cell therapy called zamtocabtagene autoleucel for different types of lymphoma, including Diffuse Large B-cell Lymphoma (DLBCL), when other treatments haven't worked. It looks at how well it works and if it's safe.
For: Refractory Diffuse Large B Cell Lymphoma (DLBCL) · Relapsed Diffuse Large B Cell Lymphoma · High Grade B-cell Lymphoma (HGBCL)United States · Canada - Not yet recruitingPHASE3
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
This study looks at a new treatment called AZD0120 for people with newly diagnosed multiple myeloma. It compares AZD0120 to a standard stem cell transplant to see which is better at stopping the cancer from growing.
For: Newly Diagnosed Multiple Myeloma (NDMM)United States · Australia · Brazil - RecruitingPHASE1
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
This study is testing a new cell therapy called CC-97540 for severe autoimmune diseases like lupus and rheumatoid arthritis. It aims to see if it's safe, how well it works, and how the body handles it, especially when other treatments haven't helped.
For: Systemic Lupus Erythematosus · Idiopathic Inflammatory Myopathy · Systemic SclerosisUnited States · Belgium · France - Active not recruitingPHASE2, PHASE3
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
This study looks at new treatments for adults with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) who are having a stem cell transplant. It aims to improve transplant success and reduce relapse.
For: Acute Myeloid Leukaemia · High-risk Myelodysplastic SyndromeUnited Kingdom - Active not recruitingPHASE3
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
This study is looking at a new treatment called axicabtagene ciloleucel for follicular lymphoma that has come back or hasn't responded to other treatments. It compares this new treatment to standard care to see how well it works.
For: Relapsed/Refractory Follicular LymphomaUnited States · France · Germany - RecruitingPHASE1, PHASE2
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
This study looks at new treatments, KITE-363 and KITE-753, for B-cell lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective these new drugs are for patients.
For: Relapsed and/or Refractory B-cell LymphomaUnited States · Australia · Canada - Active not recruitingPHASE2
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
This study is looking at a new T-cell therapy called Lete-Cel for people with advanced synovial sarcoma or myxoid/round cell liposarcoma. It aims to see how safe and effective this treatment is in fighting these cancers.
For: NeoplasmsUnited States · Canada · France - Active not recruitingPHASE2
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
This study compares two ways to prepare adults with acute lymphoblastic leukaemia (ALL) for a stem cell transplant. It aims to find out if a slightly stronger treatment can better stop the cancer from coming back, without making the transplant recovery harder.
For: Acute Lymphoblastic LeukemiaUnited Kingdom - Active not recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
This study is testing a new cell therapy called JCAR017 for adults with certain types of non-Hodgkin lymphoma that has returned or hasn't responded to other treatments. It aims to see how well it works and if it's safe.
For: Lymphoma, Non-HodgkinUnited States · Austria · Canada - Active not recruitingPHASE3
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
This study compares a new cell therapy (ide-cel) plus standard maintenance medicine (lenalidomide) against lenalidomide alone for adults with newly diagnosed multiple myeloma. It's for those who haven't fully responded to their initial stem cell transplant.
For: Multiple MyelomaUnited States · Australia · Austria